Histogen, Inc.
Industry
- Research, Analytical Equipment & Supplies
- Medical Devices
- Biomaterials
- Pharmaceuticals
- Biotechnology
- Large Molecule
Latest on Histogen, Inc.
Cost-cutting has become the norm for biopharmaceutical companies in 2023 as drug developers struggle to raise capital for ongoing research and development programs, never mind bringing in new funding
Since it has become difficult for many biopharmaceutical companies to raise money during the past year and a half, several firms have been forced to cut costs to make remaining cash balances last long
A public company since its reverse merger with Histogen, Inc. in April 2019, Ocugen Inc. has not walked the smoothest path, but it thinks it can offer significant benefit to retinitis pigmentosa p
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Histogen’s Regenerative Medi